Short Interest in Pluri Inc. (NASDAQ:PLUR) Decreases By 14.0%

Pluri Inc. (NASDAQ:PLUR) was the target of a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 25,800 shares, a decline of 14.0% from the February 13th total of 30,000 shares. Based on an average trading volume of 12,700 shares, the short-interest ratio is presently 2.0 days. Currently, 0.7% of the company’s shares are short sold.

Pluri Trading Up 0.3 %

Shares of NASDAQ PLUR traded up $0.02 during trading on Wednesday, hitting $4.43. 2,234 shares of the company were exchanged, compared to its average volume of 18,073. The firm has a market capitalization of $30.96 million, a PE ratio of -0.79 and a beta of 1.76. Pluri has a 12-month low of $4.07 and a 12-month high of $8.40. The company has a fifty day moving average price of $4.46 and a 200-day moving average price of $4.82. The company has a debt-to-equity ratio of 4.44, a quick ratio of 5.04 and a current ratio of 5.04.

Pluri (NASDAQ:PLUR) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.53) earnings per share (EPS) for the quarter. Pluri had a negative net margin of 3,551.49% and a negative return on equity of 2,778.13%.

Institutional Trading of Pluri

A hedge fund recently raised its stake in Pluri stock. Renaissance Technologies LLC boosted its stake in Pluri Inc. (NASDAQ:PLUR) by 38.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 34,025 shares of the company’s stock after buying an additional 9,400 shares during the period. Renaissance Technologies LLC owned approximately 0.61% of Pluri worth $145,000 at the end of the most recent quarter. Institutional investors and hedge funds own 16.59% of the company’s stock.

Pluri Company Profile

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.